8-K: Bionano Genomics Reports Q4 and Full-Year 2024 Results, Provides 2025 Revenue Outlook

Bionano Genomics reports a decrease in revenue for Q4 and full-year 2024, but highlights cost reduction efforts and provides a revenue outlook for 2025.

Summary

• Bionano Genomics reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a revenue outlook for 2025.
• The company faced a challenging external environment with shrinking capital budgets and financial uncertainty for customers.
• Bionano has reduced the annualized cost of operating the business by approximately $100 million since May 2023.
• The installed base of OGM systems totaled 371 at year-end, a 14% increase over 2023.
• The company sold 8,058 nanochannel array flowcells in Q4 and 30,307 flowcells during 2024, a 15% increase year-over-year.
• Total revenue for Q4 2024 was $8.2 million, a 24% decrease compared to Q4 2023, which included $2.0 million from discontinued clinical services.
• GAAP gross margin for Q4 2024 was 42%, significantly higher than the 23% reported for Q4 2023.
• Full year 2024 revenue was $30.8 million, a 15% decrease compared to 2023.
• Product revenue increased 1% to $27.0 million in 2024.
• The company anticipates full year 2025 revenue in the range of $29.0 to $32.0 million and Q1 2025 revenue in the range of $6.2 to $6.3 million.
• Bionano expects to install 15 to 20 new OGM systems in 2025.
• The company believes it has cash runway into the first quarter of 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue is down, cost-cutting measures are showing results, and the company is optimistic about future growth with new products and market adoption. The need for additional capital raises tempers the positive outlook.

Positives

• Significant cost reduction efforts have resulted in approximately $100 million in annualized savings.
• The installed base of OGM systems continues to grow, reaching 371 at the end of 2024.
• Flowcell sales increased by 15% year-over-year.
• GAAP gross margin improved significantly in Q4 2024, reaching 42%.
• The company has cash runway into the first quarter of 2026.
• The AMA established a category I CPT code for OGM, effective January 1, 2025, which should help with reimbursement.
• Product revenue increased 1% to $27.0 million in 2024.

Negatives

• Total revenue for Q4 2024 decreased by 24% compared to Q4 2023.
• Full year 2024 revenue decreased by 15% compared to 2023.
• Full year 2024 GAAP total gross margin was 1%, down from 26% in 2023.

Risks

• The company faces a challenging external environment with shrinking capital budgets and financial uncertainty for customers.
• The company's ability to continue as a going concern depends on obtaining sufficient financing and managing costs.
• Adverse geopolitical and macroeconomic events could impact the business.
• The company's future performance is subject to risks and uncertainties associated with its business and financial condition.

Future Outlook

The company anticipates full year 2025 revenue in the range of $29.0 to $32.0 million and Q1 2025 revenue in the range of $6.2 to $6.3 million. They also expect to install 15 to 20 new OGM systems in 2025 and believe they have cash runway into the first quarter of 2026.

Management Comments

• Erik Holmlin, PhD, president and chief executive officer of Bionano, commented that the fourth quarter of 2024 marks the seventh straight quarter of cost reduction efforts.
• Holmlin stated that the company has reduced the annualized cost of operating the business by approximately $100 million.
• Holmlin noted strong demand for their products and the newly established category I CPT code for OGM.

Industry Context

Bionano operates in the genome analysis solutions market, competing with companies offering cytogenetic and molecular diagnostic tools. The adoption of OGM and the establishment of CPT codes are key factors for market penetration. The company's focus on cost reduction and recurring revenue streams aligns with the need for sustainable growth in a competitive landscape.

Comparison to Industry Standards

• It is difficult to compare Bionano directly to industry standards without knowing the specific benchmarks for OGM technology adoption and financial performance.
• Companies like Illumina and Pacific Biosciences offer competing technologies for genome analysis, but OGM focuses specifically on structural variation.
• The 14% increase in installed OGM systems suggests growing adoption, but the overall revenue decline indicates challenges in monetizing the technology.
• The gross margin improvement is a positive sign, but the company needs to demonstrate consistent profitability to be competitive.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the cost reduction efforts and future outlook.
• Employees may be affected by restructuring and cost-cutting measures.
• Customers may benefit from the company's focus on improving its products and services.
• Creditors may be impacted by the modification of the terms of the senior secured convertible debentures.

Next Steps

• The company plans to focus on OGM and software customers that drive consistent and recurring revenues.
• Bionano will continue to implement cost savings initiatives.
• The company will focus on expanding the installed base of OGM systems.
• Bionano will continue to drive adoption of OGM and its technology solutions.

Key Dates

Keywords

Bionano Genomics, optical genome mapping, OGM, revenue, financial results, cost reduction, flowcells, gross margin, CPT code, Stratys system, VIA software